Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5 - Full Text View

Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2 - 5

This study has been terminated.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) University of Colorado at Denver and Health Sciences Center
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000330

Purpose

The purpose of this study is to assess the abuse liability and reinforcing effects of intravenous buprenorphine and buprenorphine/naloxone combinations in heroin-dependent volunteers

Condition	Intervention	Phase
Heroin Dependence Opioid-Related Disorders	Drug: Opioid-Related Disorders	Phase II

MedlinePlus related topics:

Heroin

ChemIDplus related topics:

Naloxone Naloxone hydrochloride Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Double-Blind, Placebo Control

Official Title:	Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment II-2

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Subjective dose estimate
Observed withdrawal rating
Opioid antagonist rating
Pupil diameter
Analog rating scale for drug effects
Drug effect characteristics
Drug/Money Preferences

Estimated Enrollment:	0
Study Start Date:	October 1999

Detailed Description:

not available at this time

Eligibility

Ages Eligible for Study:	18 Years to 65 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Individuals must be at least 18 yrs of age, currently opioid dependent and must not be seeking treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency and have a history of IV opioid use.

Exclusion Criteria:

Individuals with evidence of an active DSM-IV Axis I psychiatric disorder (e.g. psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000330

Locations


United States, Colorado
	University of Colorado Health Sciences Center
	Denver, Colorado, United States, 80206

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

University of Colorado at Denver and Health Sciences Center

Investigators


Principal Investigator:	Leslie Amass, Ph.D.	University of Colorado at Denver and Health Sciences Center

More Information

Study ID Numbers:	NIDA-11160-5, R01-11160-5
First Received:	September 20, 1999
Last Updated:	November 3, 2005
ClinicalTrials.gov Identifier:	NCT00000330
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Buprenorphine

Mental Disorders

Heroin Dependence

Substance-Related Disorders

Disorders of Environmental Origin

Opioid-Related Disorders

Naloxone

Additional relevant MeSH terms:

Sensory System Agents

Therapeutic Uses

Narcotic Antagonists

Physiological Effects of Drugs

Central Nervous System Depressants

Narcotics

Peripheral Nervous System Agents

Analgesics

Central Nervous System Agents

Pharmacologic Actions

Analgesics, Opioid

ClinicalTrials.gov processed this record on September 05, 2008